Rangering i aksjer
#38628
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company based in the... Poolbeg Pharma plc is a clinical-stage biopharmaceutical company based in the United Kingdom, focused on developing treatments for infectious diseases. Its pipeline features several key programs: POLB 001, a p38 MAP Kinase inhibitor intended for severe influenza; POLB 002, a pioneering, in-licensed RNA-based immunotherapy administered intranasally to combat respiratory virus infections; and POLB 003, an intramuscular vaccine aimed at preventing Melioidosis. Beyond specific therapeutic candidates, Poolbeg also holds licensed access to advanced micro- and nanoencapsulation technology for an oral vaccine delivery system designed to stimulate gut immunity. The company further advances its research through an artificial intelligence-powered drug program. Additionally, Poolbeg is developing a biomarker platform to identify individuals at high risk of severe disease, alongside a model-derived vaccine discovery platform to pinpoint novel vaccine candidates. Incorporated in 2021, Poolbeg Pharma plc is headquartered in London.
Handel Poolbeg Pharma PLC (POLB)
Pris POLB pris med markedsverdi på B
Markedsverdi av Poolbeg Pharma PLC(POLB)
Markedsverdi: $882.99K
Per August 2026 har Poolbeg Pharma PLC en markedsverdi på $882.99K. Dette gjør Poolbeg Pharma PLC til det 38628th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Poolbeg Pharma PLC fra 2021 til 2026
POLB sammenlignet med topp 5 mest populære stocks
| Pris på POLB |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.457T
|
+617,959,026.73%
|
|
|
|
|
$4.494T
|
+508,924,351.87%
|
|
|
|
|
$4.161T
|
+471,292,844.65%
|
|
|
|
|
$3.687T
|
+417,530,730.81%
|
|
|
|
|
$2.832T
|
+320,682,675.20%
|
